» Articles » PMID: 20194495

PrP Conformational Transitions Alter Species Preference of a PrP-specific Antibody

Abstract

The epitope of the 3F4 antibody most commonly used in human prion disease diagnosis is believed to consist of residues Met-Lys-His-Met (MKHM) corresponding to human PrP-(109-112). This assumption is based mainly on the observation that 3F4 reacts with human and hamster PrP but not with PrP from mouse, sheep, and cervids, in which Met at residue 112 is replaced by Val. Here we report that, by brain histoblotting, 3F4 did not react with PrP of uninfected transgenic mice expressing elk PrP; however, it did show distinct immunoreactivity in transgenic mice infected with chronic wasting disease. Compared with human PrP, the 3F4 reactivity with the recombinant elk PrP was 2 orders of magnitude weaker, as indicated by both Western blotting and surface plasmon resonance. To investigate the molecular basis of these species- and conformer-dependent preferences of 3F4, the epitope was probed by peptide membrane array and antigen competition experiments. Remarkably, the 3F4 antibody did not react with MKHM but reacted strongly with KTNMK (corresponding to human PrP-(106-110)), a sequence that is also present in cervids, sheep, and cattle. 3F4 also reacted with elk PrP peptides containing KTNMKHV. We concluded that the minimal sequence for the 3F4 epitope consists of residues KTNMK, and the species- and conformer-dependent preferences of 3F4 arise largely from the interactions between Met(112) (human PrP) or Val(115) (cervid PrP) and adjacent residues.

Citing Articles

Characterization of variably protease-sensitive prionopathy by capillary electrophoresis.

Myskiw J, Bailey-Elkin B, Avery K, Barria M, Ritchie D, Cohen M Sci Rep. 2024; 14(1):27867.

PMID: 39537719 PMC: 11561330. DOI: 10.1038/s41598-024-79217-1.


Large-scale validation of skin prion seeding activity as a biomarker for diagnosis of prion diseases.

Zhang W, Orru C, Foutz A, Ding M, Yuan J, Shah S Acta Neuropathol. 2024; 147(1):17.

PMID: 38231266 PMC: 11812622. DOI: 10.1007/s00401-023-02661-2.


Characterization of Prion Disease Associated with a Two-Octapeptide Repeat Insertion.

Brennecke N, Cali I, Mok T, Speedy H, Consortium G, Hosszu L Viruses. 2021; 13(9).

PMID: 34578375 PMC: 8473248. DOI: 10.3390/v13091794.


Generation of human chronic wasting disease in transgenic mice.

Wang Z, Qin K, Camacho M, Cali I, Yuan J, Shen P Acta Neuropathol Commun. 2021; 9(1):158.

PMID: 34565488 PMC: 8474769. DOI: 10.1186/s40478-021-01262-y.


Decrease in Skin Prion-Seeding Activity of Prion-Infected Mice Treated with a Compound Against Human and Animal Prions: a First Possible Biomarker for Prion Therapeutics.

Ding M, Teruya K, Zhang W, Lee H, Yuan J, Oguma A Mol Neurobiol. 2021; 58(9):4280-4292.

PMID: 33983547 PMC: 8487418. DOI: 10.1007/s12035-021-02418-6.


References
1.
Lund C, Olsen C, Tveit H, Tranulis M . Characterization of the prion protein 3F4 epitope and its use as a molecular tag. J Neurosci Methods. 2007; 165(2):183-90. DOI: 10.1016/j.jneumeth.2007.06.005. View

2.
Forloni G, Angeretti N, Chiesa R, Monzani E, Salmona M, Bugiani O . Neurotoxicity of a prion protein fragment. Nature. 1993; 362(6420):543-6. DOI: 10.1038/362543a0. View

3.
Kim S, Rahbar R, Hegde R . Combinatorial control of prion protein biogenesis by the signal sequence and transmembrane domain. J Biol Chem. 2001; 276(28):26132-40. DOI: 10.1074/jbc.M101638200. View

4.
Glatzel M, Abela E, Maissen M, Aguzzi A . Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N Engl J Med. 2003; 349(19):1812-20. DOI: 10.1056/NEJMoa030351. View

5.
Yuan J, Xiao X, McGeehan J, Dong Z, Cali I, Fujioka H . Insoluble aggregates and protease-resistant conformers of prion protein in uninfected human brains. J Biol Chem. 2006; 281(46):34848-58. DOI: 10.1074/jbc.M602238200. View